Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Topotecan in Recurrent Small Cell Lung Cancer
NCT00697476Phase 2Terminated
- Sponsor
- Armando Santoro
- Start
- Jan 2009
- Primary completion
- Sep 2009
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in small cell lung cancer (SCLC), sponsored by Armando Santoro. Primary endpoints: Maximum Tolerated Dose, Objective Response Rate and 1 more. Started Jan 2009; status: terminated.
02
Drugs
vorinostat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00697476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00697476.